Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end ‐stage renal disease

AbstractAimsTo evaluate the risk of heart failure (HF) in patients with type 2 diabetes (T2D) complicated by development of intercurrent ischaemic heart disease (IHD), end ‐stage renal disease (ESRD), or both, compared to patients with T2D and no IHD and ESRD.Methods and resultsFrom Danish nationwide registries, we identified all patients with new ‐onset T2D with no history of HF between 1998 and 2015. Landmark analyses were used to estimate the 5‐year absolute risk of HF at several follow‐up times, and accounted for the occurrence of IHD and ESRD, identified before HF. The Aalen–Johansen estimator was used to account for censoring an d the competing risk of death. A total of 285 024 patients with new‐onset T2D were included. During follow‐up, 19 960 developed incident HF. Among patients with T2D free of HF 5 years after T2D diagnosis, patients without IHD and ESRD had the lowest 5‐year risk of HF [4.02%; 95% confiden ce interval (CI) 3.90–4.15), those with T2D complicated by IHD [11.51%; relative risk (RR) 2.86; 95% CI 2.72–3.02;P 
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research

Related Links:

ConclusionsThe HRQoL of T2DM inpatients with a complication was considerably impaired. Our estimates provide supplementary data for public health and cost-effectiveness modeling, and increase the breadth of knowledge of HRQoL in T2DM.
Source: Quality of Life Research - Category: Health Management Source Type: research
res E Abstract Ischemic heart disease is the main cause of death globally. In the heart, the ischemia/reperfusion injury gives rise to a complex cascade of molecular signals, called cardiac remodeling, which generates harmful consequences for the contractile function of the myocardium and consequently heart failure. Metformin is the drug of choice in the treatment of type 2 diabetes mellitus. Clinical data suggest the direct effects of this drug on cardiac metabolism and studies in animal models showed that metformin activates the classical pathway of AMP-activated protein kinase (AMPK), generating cardioprotectiv...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
Obesity is a serious, chronic, treatable, and global disease epidemic. Over 98 million people currently have the disease of obesity, and in a recent New England Journal of Medicine article, Harvard researchers predicted that by 2030, 50% of the population in the United States will have the disease of obesity. Type 2 diabetes (T2D) is significantly associated with obesity. While many people with obesity do not have diabetes, most people with T2D have the disease of obesity. Excess adiposity (body fat storage), which is present in obesity, contributes to many chronic diseases beyond T2D. These include high blood pressure, he...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Diabetes Diet and Weight Loss Health Heart Health Surgery Source Type: blogs
This study is par for the course, looking at Japanese Olympic participants. Interestingly, it hints at the upper end of the dose-response curve for physical activity, in that a longer career as a professional athlete may be detrimental in comparison to lesser degrees of exercise and training. From this large, retrospective cohort study targeting 3546 Japanese Olympic athletes, we observed significant lower mortality among Olympians compared with the Japanese general population. The overall standardised mortality ratio (SMR) was 0.29. The results were consistent with previous studies conducted in other non-Asian co...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: Our data suggest a potential use of treprostinil as an early treatment for mild metabolic syndrome-associated PH-HFpEF and that combined treatment with treprostinil and metformin may improve hyperglycemia and cardiac function in a more severe disease. PMID: 32268788 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Tags: Arterioscler Thromb Vasc Biol Source Type: research
AbstractAimsTo evaluate the risk of heart failure (HF) in patients with type 2 diabetes (T2D) complicated by development of intercurrent ischaemic heart disease (IHD), end ‐stage renal disease (ESRD), or both, compared to patients with T2D and no IHD and ESRD.Methods and resultsFrom Danish nationwide registries, we identified all patients with new ‐onset T2D with no history of HF between 1998 and 2015. Landmark analyses were used to estimate the 5‐year absolute risk of HF at several follow‐up times, and accounted for the occurrence of IHD and ESRD, identified before HF. The Aalen–Johansen estimator was used ...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
You may have already heard the term “insulin resistance,” as it has been widely discussed by doctors and the media. But did you know that you can reduce or reverse it in the vast majority of people? Insulin resistance, i.e., the inability of the body’s cells, especially liver, muscle, and brain, to respond to insulin and allow blood sugar to enter cells, drives numerous abnormal health conditions including type 2 diabetes, hypertension, coronary heart disease, fatty liver, Alzheimer’s dementia, and cancer. It is therefore a driving force behind so many modern and common chronic health conditions. Yo...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: Open can belly fat can insulin resistance be reversed lose weight reduce belly fat reverse inflammation visceral fat wheat belly Source Type: blogs
Type 2 diabetes (T2D) is a metabolic disorder of insulin resistance — a reduced sensitivity to the action of insulin — which leads to high blood sugar, or hyperglycemia. Approximately 12% of American adults have T2D, and more than one-third of Americans have prediabetes, a precursor to T2D. This is a major public health concern, as T2D dramatically increases risk for heart disease, including heart attacks, atrial fibrillation, and heart failure. The development and progression of T2D is affected by many factors. Some, such as a person’s race/ethnicity, age, and gender cannot be modified. Others, including...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Diabetes Exercise and Fitness Healthy Eating Heart Health Source Type: blogs
Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
More News: Cardiology | Denmark Health | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Disease | Heart Failure